|Application ||WB, ICC, E|
|Other Accession||NP_277038, 90427|
|Calculated MW||Predicted: 20 kDa |
Observed: 25 kDa
|Application Notes||Bmf antibody can be used for detection of Bmf by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 5 μg/mL.|
|Other Names||Bmf Antibody: Bcl-2-modifying factor, Bcl2 modifying factor|
|Target/Specificity||Bmf antibody was raised with a synthetic peptide corresponding to 15 amino acids near the amino terminus of human Bmf.|
The immunogen is located within the first 50 amino acids of Bmf.
|Reconstitution & Storage||Bmf antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||Bmf Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May play a role in apoptosis. Isoform 1 seems to be the main initiator.|
|Tissue Location||Isoform 1 is mainly expressed in B-lymphoid cells. Isoform 2 and isoform 3 are mainly expressed in B-CLL and normal B-cells.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Bmf Antibody: Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor). The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program. Bmf is constitutively expressed in many tissues.
Puthalakath H, Villunger A, O'Reilly LA, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293:1829-32.
Hunt A and Evan G. Apoptosis. Till death us do part. Science 2001; 293:1784-5.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.